<SEC-DOCUMENT>0001193125-19-165320.txt : 20190605
<SEC-HEADER>0001193125-19-165320.hdr.sgml : 20190605
<ACCEPTANCE-DATETIME>20190604200133
ACCESSION NUMBER:		0001193125-19-165320
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190603
FILED AS OF DATE:		20190605
DATE AS OF CHANGE:		20190604

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		19878290

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d758824d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated June&nbsp;3, 2019 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 12, 95 Pitt Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Sydney, 2000 New South Wales, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by
furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Immutep Presentation at ASCO 2019</TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: June&nbsp;3, 2019 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><U></U>Title:&nbsp;&nbsp;&nbsp;Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d758824dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g758824g48c57.gif" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:3.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep
Presentation at ASCO 2019 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; 3</B><B></B><B>&nbsp;June</B><B> 2019 &#150;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ:
IMMP) (&#147;Immutep&#148; or &#147;the Company&#148;), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to confirm that it was involved in two poster presentations at the American
Society of Clinical Oncology&#146;s (ASCO) Annual Meeting, in Chicago, Illinois taking place from May 31<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> &#150; June&nbsp;4, 2019. The two posters related to Immutep&#146;s lead product
candidate eftilagimod alpha (&#147;efti&#148; or &#147;IMP321&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The first poster (TPS2667&nbsp;&#150; #299b) provided an overview of the ongoing
Phase II <FONT STYLE="white-space:nowrap">TACTI-002</FONT> (<B><U>T</U></B>wo <B><U>ACT</U></B>ive <B><U>I</U></B>mmunotherapies) clinical trial. <FONT STYLE="white-space:nowrap">TACTI-002</FONT> is being conducted by Immutep in collaboration with
Merck&nbsp;&amp; Co., Inc., Kenilworth, NJ, USA (known as &#147;MSD&#148; outside the United States and Canada). This multicenter Phase II clinical trial is evaluating the combination of efti with MSD&#146;s KEYTRUDA&reg; (or pembrolizumab, an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy) in up to 109 patients with second line head and neck squamous cell carcinoma or <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer in first
and second line. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This poster, presented by Dr.&nbsp;Julio Antonio Peguero, MD of Oncology Consultants PA, 2130 W. Holcombe Blvd. 10<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> Floor, Houston, TX 77030, outlined the ongoing <FONT STYLE="white-space:nowrap">TACTI-002</FONT> clinical trial, its design and primary end points. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The second poster related to efti (TPS2651&nbsp;&#150; #291b) provided an overview of the two additional INSIGHT clinical trial stratas of the prospective
investigator-initiated phase I study. Stratum D of the clinical trial is being conducted in collaboration with Merck KGaA, Darmstadt, Germany and Pfizer Inc. This explorative, open-labeled Phase I study will evaluate the feasibility and safety of
subcutaneous efti injections combined with either <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> drug therapy or BAVENCIO<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (or avelumab, <FONT
STYLE="white-space:nowrap">PD-L1</FONT> inhibitor) in patients with advanced-stage solid tumors. The Institute of Clinical Cancer Research, Krankenhaus Nordwest GmbH in Frankfurt, Germany (&#147;IKF&#148;) will be the sponsor of the clinical trial
and it will be conducted under the existing protocol of the ongoing INSIGHT clinical study. Stratum D is open for recruitment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This poster, presented by
Dr.&nbsp;Daniel Wilhelm Mueller, PhD, of the Institute of Clinical Cancer Research, Krankenhaus Nordwest GmbH in Frankfurt, Germany, outlined the planned two new strata of the INSIGHT clinical trial, its design and primary end points. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ASCO poster regarding the Company&#146;s <FONT STYLE="white-space:nowrap">TACTI-002</FONT> trial can be found at
https://www.immutep.com/investors-media/presentations.html </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Avelumab Approved Indications </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Avelumab (BAVENCIO<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) in combination with axitinib is indicated in the US for the first-line treatment
of patients with advanced renal cell carcinoma (RCC). </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g758824g48c57.gif" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:3.00pt solid #000000">&nbsp;</P>
<P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The US Food and Drug Administration (FDA) also granted accelerated approval for avelumab (BAVENCIO<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) for the treatment of (i)&nbsp;adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (mMCC) and (ii)&nbsp;patients with locally advanced or metastatic urothelial
carcinoma (mUC) who have disease progression during or following platinum-containing chemotherapy, or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. These indications are
approved under accelerated approval based on tumor response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Avelumab is currently approved for patients with MCC in more than 45 countries globally, with the majority of these approvals in a broad indication that is
not limited to a specific line of treatment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Avelumab Important Safety Information from the US <FONT STYLE="white-space:nowrap">FDA-Approved</FONT>
Label </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The warnings and precautions for avelumab (BAVENCIO<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) include immune-mediated adverse
reactions (such as pneumonitis and hepatitis [including fatal cases], colitis, endocrinopathies, nephritis and renal dysfunction and other adverse reactions [which can be severe and have included fatal cases]), infusion-related reactions, major
adverse cardiovascular events (MACE), and embryo-fetal toxicity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Common adverse reactions (reported in at least 20% of patients) in patients treated with
BAVENCIO<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> include fatigue, musculoskeletal pain, diarrhea, nausea, infusion-related reaction, peripheral edema, decreased appetite/hypophagia, urinary tract infection and rash. Additional
common adverse reactions reported in patients receiving BAVENCIO<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in combination with axitinib include hypertension, mucositis, palmar-plantar erythrodysesthesia, dysphonia, hypothyroidism,
hepatotoxicity, cough, dyspnea, abdominal pain, and headache. Clinical chemistry and hematology laboratory value abnormalities have been reported including but not limited to <FONT STYLE="white-space:nowrap">grade&nbsp;3-4</FONT> lymphopenia,
anemia, elevated cholesterol and liver enzymes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For full Prescribing Information and Medication Guide for BAVENCIO<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, please see www.BAVENCIO.com. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a globally active biotechnology company that is a leader in the development of immunotherapeutic products for the treatment of cancer and autoimmune
disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the
NASDAQ (IMMP) in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep&#146;s current lead product candidate is eftilagimod alpha (&#147;efti&#148; or &#147;IMP321&#148;), a
soluble <FONT STYLE="white-space:nowrap">LAG-3Ig</FONT> fusion protein based on the <FONT STYLE="white-space:nowrap">LAG-3</FONT> immune control mechanism. This mechanism plays a vital role in the regulation of the T cell immune response. Efti is
currently in a Phase IIb clinical trial as a chemoimmunotherapy for metastatic breast cancer termed AIPAC (clinicaltrials.gov identifier NCT02614833); a Phase II clinical trial being conducted in collaboration with Merck&nbsp;&amp; Co., Inc.,
Kenilworth, NJ, USA (known as &#147;MSD&#148; outside the United States and Canada) referred to as <FONT STYLE="white-space:nowrap">TACTI-002</FONT> (Two ACTive Immunotherapies) to evaluate a combination of efti with KEYTRUDA<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (pembrolizumab) in several different solid tumours (clinicaltrials.gov identifier NCT03625323); a planned Phase I clinical trial in collaboration with Merck KGaA, Darmstadt, Germany and Pfizer
Inc. referred to as <FONT STYLE="white-space:nowrap">INSIGHT-004</FONT> to evaluate a combination of efti with avelumab (clinical trials.gov identifier NCT03252938); and a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel
(clinicaltrials.gov identifier NCT02676869). </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g758824g48c57.gif" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:3.00pt solid #000000">&nbsp;</P>
<P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further information can be found on the Company&#146;s website <U>www.immutep.com</U> or by contacting: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Investors: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jay Campbell, Chief Business Officer,
Immutep Limited </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (917) <FONT STYLE="white-space:nowrap">860-9404;</FONT> <U>jay.campbell@immutep.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Matthew Gregorowski,
Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 2 8234 0105; <U>mgregorowski@citadelmagnus.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Garth Russell, LifeSci Advisors </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (646) <FONT STYLE="white-space:nowrap">876-3613;</FONT> <U>garth@lifesciadvisors.com</U> </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g758824g48c57.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g758824g48c57.gif
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MO7.UC&.U<YS&I0
M
M
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M5W>H,C^?IW/#Q KM-PBE0CL/L%/ IS8]4SMXDWJ&H'_[_J9VQV)^ T JDP$
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..CN[XCO 8C_+(#8$  #L!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
